美托洛尔和卡维地洛治疗扩张型心肌病心力衰竭的Meta分析  

Meta-analysis of Carvediol and Metoprolo in treatment of dilated car-diomyopathy with heart failure

作　　者：张尧[1] 唐其柱[1] 张宁[1] 周梦桥[1] 

机构地区：[1]武汉大学人民医院心血管内科,湖北武汉430060

出　　处：《中国医药导报》2015年第21期126-130,共5页China Medical Herald

摘　　要：目的评价美托洛尔和卡维地洛治疗扩张型心肌病心力衰竭的效果。方法检索中国生物医学文献数据库、中国知网、万方、维普、Pub Med、Cochrane图书馆、EMbase中关于美托洛尔和卡维地洛治疗扩张型心肌病心力衰竭的随机对照试验,同时筛检纳入文献的参考文献,并对文献质量进行严格评价和资料提取,对符合质量标准的研究使用Rev Man 5.1进行Meta分析。结果共纳入6篇文献,共438例患者。结果显示,与美托洛尔比较,卡维地洛治疗扩张型心肌病心力衰竭在临床有效率(OR=0.27,95%CI:0.15~0.48,P<0.000 01)、左心室射血分数(MD=-3.10,95%CI:-4.75^-1.44,P=0.0002)、左心室舒张末期内径(MD=2.3,95%CI:0.89~3.71,P=0.001)方面具有良好的疗效,差异有统计学意义。结论卡维地洛可以改善扩张型心肌病心力衰竭的左心室射血分数、左心室舒张末期内径,提高临床有效率,值得推广。Objective To review the efficacies of Carvediol and Metoprolo in treatment of dilated cardiomyopathy with heart failure. Methods The randomized controlled trials about the effieaeies of Carvediol and Metoprolo in treatment of dilated eardiomyopathy with heart failure were retrieved from the databases of Chinese biomedical database, CNKI, Wanfang, VIP, PubMed, Coehrane library, EMbase. The references of enrolled literatures were screened, and the quality of references was evaluated strictly and the data was extracted, and then the studies met with the quality specification were taken a Meta-analysis by RevMan 5.1 software. Results Totally 6 references were included, 438 patients in total. The results showed that, compared with Metoprolo, the clinical effective rate （OR = 0.27, 95%CI： 0.15-0.48, P 〈 0.000 01）, left ventrieular ejection fraction （MD = -3.10, 95%CI： -4.75 to -1.44, P = 0.0002）, left ventricular end-diastolic inner diameter （MD = 2.3, 95%CI： 0.89-3.71, P = 0.001） in Carvediol group had good effects, the differences were statistical- ly significant. Conclusion Carvediol can significantly improve left ventrieular ejection fraction and left ventricular endL diastolic inner diameter of dilated cardiomyopathy with heart failure, improve the clinical effective rate, which deserves promotion.

关 键 词：卡维地洛 美托洛尔 扩张型心肌病 心力衰竭 META分析 

分 类 号：R542.22[医药卫生—心血管疾病]